Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) was downgraded by equities research analysts at SVB Securities from an “outperform” rating to a “market perform” rating in a research report issued on Friday, FlyOnTheWall reports. Several other analysts have also commented on the stock. Stifel Nicolaus lowered shares of Reata Pharmaceuticals from a “buy” rating to […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) was downgraded by research analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued on Friday, FlyOnTheWall reports. RETA has been the topic of several other research reports. Stifel Nicolaus cut shares of Reata Pharmaceuticals from a “buy” rating to […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating in a note issued to investors on Friday, FlyOnTheWall reports. RETA has been the subject of several other reports. Stifel Nicolaus lowered Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on […]
Reata Pharmaceuticals (NASDAQ:RETA – Free Report) had its price target lifted by Cantor Fitzgerald from $110.00 to $145.00 in a report issued on Monday, MarketBeat Ratings reports. They currently have an overweight rating on the stock. RETA has been the topic of several other reports. SVB Securities raised Reata Pharmaceuticals from a market perform rating […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) had its price target boosted by investment analysts at Cantor Fitzgerald from $110.00 to $145.00 in a research note issued to investors on Monday, FlyOnTheWall reports. Cantor Fitzgerald’s price objective would suggest a potential upside of 30.80% from the stock’s current price. Other research analysts have also recently […]